|
|
|
|
|
06.06.25 - 14:00
|
Alvotech and Dr. Reddy’s partner for Keytruda biosimilar (PBR)
|
|
|
The alliance leverages both companies' experience in the field of biosimilars. By combining their resources, they aim to expedite the development process while expanding the product's availability worldwide.
The post Alvotech and Dr. Reddy's partner for Keytruda biosimilar appeared first on Pharmaceutical Business review....
|
|
|
|
|
05.06.25 - 09:00
|
Alvotech and Dr. Reddy′s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab) (GlobeNewswire EN)
|
|
|
HYDERABAD, India and REYKJAVIK, Iceland, June 05, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide (“Alvotech”), and Dr. Reddy's Laboratories Ltd., (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as “Dr. Reddy's”), today announced that the companies have entered into a collaboration and license agreement to co-develop, manufacture and commercialize a biosimilar candidate to Keytruda® (pembrolizumab) for global markets. Keytruda® (pembrolizumab) is indicated for the treatment of numerous cancer types. In 2024, worldwide sales of Keytruda were US$29.5 billion [1]. The collaboration combines Dr. Reddy's and Alvotech's proven capabilities in biosimilars, thereby, speeding up the development process and extending the global reach for this biosimilar candidate....
|
|
|
|
|
|
|
|
|
09.05.25 - 20:54
|
Dr. Reddy′s Q4 & Full Year FY25 Financial Results (Business Wire)
|
|
|
HYDERABAD, India--(BUSINESS WIRE)--$RDY #DRREDDY--Dr. Reddy's Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY) today announced its consolidated financial results for the quarter and year ended March 31, 2025. The information mentioned in this release is based on consolidated financial statements under International Financial Reporting Standards (IFRS).
Q4FY25
FY25
Revenues
₹ 85,060 Mn
₹ 325,535 Mn
[Up: 20% YoY^; 2% QoQ]
[Up: 17% YoY^]
Gross Margin
55.6%
58.5%
[Q4FY24: 58.6%; Q3FY25: 58.7%]
[FY24: 58.6%]
SG&A Expenses
₹ 24,055 Mn
₹ 93,870 Mn
[Up: 17% YoY; Flat QoQ]
[Up: 22% YoY]
R&D Expenses
₹ 7,258 Mn
₹ 27,380 Mn
[8.5% of Revenues]
[8.4% of Revenues]
EBITDA
₹ 24,749 Mn
₹ 92,133 Mn
[29.1% of Revenues]
[28.3% of Revenues]
Profit before Tax
₹ 20,054* Mn
₹ 76,784* Mn
[Up: 25% YoY; 7% QoQ]
[Up: 7% YoY]
Profit after Tax
₹ 15,939 Mn
₹ 56,544 Mn
attributable to Equity Holders
[Up: 22% YoY; 13% QoQ]
[Up: 2% YoY]
^Includ...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
27.03.25 - 16:49
|
Bio-Thera and Dr. Reddy′s Execute Exclusive Commercialization Agreement for BAT2206, a Proposed Stelara® Biosimilar, and BAT2506, a Proposed Simponi® Biosimilar, for Southeast Asia (PR Newswire)
|
|
|
GUANGZHOU, China and HYDERABAD, India, March 27, 2025 /PRNewswire/ -- Bio-Thera Solutions (688177:SH; "Bio-Thera"), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, and Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr.......
|
|
|
|
|
|
|
04.03.25 - 13:06
|
Pediatrica Health Group Acquires the Rainbow Pediatric Center Group of Practices and Sets a Course for Change (Business Wire)
|
|
|
MIAMI & JACKSONVILLE, Fla.--(BUSINESS WIRE)--Miami-based Pediatrica Health Group, a multi-site, pediatric primary care organization dedicated to providing equitable access to innovative care for kids, today announced the completed acquisition of the Rainbow Pediatric Center group of practices owned and operated by Dr. Prasanthi Reddy. Through this acquisition of 4 locations, 15 providers, and a patient panel of approximately 12,000 kids, Pediatrica will put in motion plans to create a Next Generation CareSM experience for patient families, a concept that resonates deeply with Dr. Reddy's vision for the future of pediatric primary care.
Next Generation Care for the Next GenerationSM
In recent years, value-based care has been the standard to aspire to for most practitioners – the idea that providers are working collaboratively to manage the patient's overall health. Next Generation CareSM, founded on this concept, goes above and beyond, putting the patient at the center of a care community tailored to m...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
